EVLO (Evelo Biosciences) Loans Receivable: $0.00 Mil (As of Sep. 2023)


What is Evelo Biosciences Loans Receivable?

Evelo Biosciences EVLO Loans Receivable is $0.00 Mil as of Sep. 2023.

Evelo Biosciences's Loans Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Evelo Biosciences Loans Receivable Related Terms

Evelo Biosciences Loans Receivable Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Loans Receivable Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Evelo Biosciences (EVLO) has a Loans Receivable of $0.00 Mil as of Sep. 2023. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Loans Receivable too high?
Evelo Biosciences' current Loans Receivable is $0.00 Mil.
How does Evelo Biosciences' Loans Receivable compare to IMNN and EDSA?
Evelo Biosciences' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Loans Receivable is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.